. 2018 Dec 20;5(2):e000706. doi: 10.1136/openhrt-2017-000706

Table 2.

Baseline mean HbA1c, baseline mean fasting plasma glucose (FPG), percentage of known diabetes and diabetes duration

Study, year	Study group	Baseline mean HbA1 (%)	Baseline mean FPG (mmol/L)	Percentage of known diabetes	Diabetes duration (year)
Budania et al,⁸ 2013	Ranolazine	n/a	7.8	100	n/a
Budania et al,⁸ 2013	Placebo	n/a	7.2	100	n/a
Eckel et al,¹⁸ 2015	Ranolazine	8.1	9.6	100	3
Eckel et al,¹⁸ 2015	Placebo	8.0	9.6	100	3
Kipnes et al, ¹⁹ 2011	Ranolazine	8.4	8.6	100	8.7
Kipnes et al, ¹⁹ 2011	Placebo	8.5	9.6	100	9.7
Kosiborod et al,⁹ 2013	Ranolazine	7.3		100	7.2
Kosiborod et al,⁹ 2013	Placebo	7.3		100	7.7
Morrow et al, 2009	Ranolazine	6.2 (all) 7.5 (diabetic)	n/a	33.1	n/a
Morrow et al, 2009	Placebo	6.2 (all) 7.5 (diabetic)	n/a	35.3	n/a
Pettus et al, 2015 – glimepiride add-on study	Ranolazine	9.8	9.8	100	7.1
Pettus et al, 2015 – glimepiride add-on study	Placebo	9.8	9.8	100	7
Pettus et al, 2015 – metformin add-on study	Ranolazine	9.4	9.4	100	6.4
Pettus et al, 2015 – metformin add-on study	Placebo	9.4	9.4	100	6.7
Timmis et al, 2005	Ranolazine 1000 mg twice daily	7.92	9.2 (n=57, diabetic)	100	n/a
	Ranolazine 750 mg twice daily	7.65	9.4 (n=63, diabetic)	100	n/a
	Placebo	7.46	9.9 (n=49, diabetic)	100	n/a